RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses.

Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 confirms that the BIR is giving effect to the Food and Drug Administration’s May 22, 2023 endorsement updating the list of VAT-exempt products under Republic Act No. 10963, or the TRAIN Law, and Republic Act No. 11534, or the CREATE Act. The practical consequence is direct: certain medicines are newly included in the VAT-exempt list, one hypertension medicine is corrected, and one cancer medicine is deleted from the list.

What Changed Under RMC No. 72-2023

RMC No. 72-2023 publishes the full text of the May 22, 2023 letter from the Food and Drug Administration of the Department of Health endorsing updates to the list of VAT-exempt medicines under the TRAIN Law and the CREATE Act. The circular is addressed to all internal revenue officers and others concerned, but its operational impact is felt by businesses that sell, purchase, distribute, prescribe, dispense, account for, or claim VAT treatment on covered medicines.

The BIR identifies three categories of updates. First, there is an inclusion of certain medicines for cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness, and tuberculosis. Second, there is a correction of a medicine for hypertension. Third, there is a deletion of a medicine for cancer. These changes matter because a medicine’s inclusion in or deletion from the VAT-exempt list affects how it should be treated in sales invoicing, procurement, accounting, VAT return preparation, and internal tax compliance checks.

For business owners and corporate accountants, the key point is that RMC No. 72-2023 is not merely an informational issuance. It signals that taxpayers should align their VAT treatment with the latest FDA-endorsed list. A medicine that is newly included should not be treated in the same manner as an ordinary VATable product once the VAT exemption becomes effective. Conversely, a medicine deleted from the list should not continue to be treated as VAT-exempt merely because it previously appeared in an older list.

Who Is Affected by the Updated VAT-Exempt Medicines List

The most affected taxpayers are pharmacies, drugstores, hospitals, medical clinics, healthcare groups, medicine wholesalers, pharmaceutical distributors, importers, and retailers. The circular is also relevant to corporate employers with healthcare procurement programs, HMOs and healthcare administrators dealing with medicine costs, and accounting teams responsible for VAT reporting on pharmaceutical purchases and sales.

For pharmacies and hospitals, the compliance issue is operational. Their inventory databases, billing systems, and medicine codes should distinguish between VAT-exempt medicines and VATable items. For pharmaceutical distributors and importers, the issue extends to price quotations, sales documentation, and customer communications. For CFOs and tax managers, the concern is whether VAT returns, sales reports, and accounting records properly reflect the status of the medicines affected by the FDA-endorsed update.

The search terms that businesses are likely to use for this issuance include RMC 72-2023 VAT exempt medicines, updated VAT-exempt medicines Philippines, VAT exemption cancer diabetes hypertension medicines, FDA list VAT exempt medicines CREATE Act, and BIR VAT-exempt medicines TRAIN Law. These phrases all point to the same practical question: which medicines should now be treated as VAT-exempt, and when should the updated treatment begin?

Effective Date and Compliance Timing

RMC No. 72-2023 specifically refers to the clarification in Q&A No. 1 of RMC No. 99-2021. According to the circular, the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the list. This timing rule is important because the relevant date is not simply the date when a taxpayer internally updates its system, nor the date when a business first becomes aware of the BIR circular.

The issuance itself is dated June 20, 2023. However, the circular refers to the FDA’s May 22, 2023 letter endorsing the updates. Businesses should therefore verify the FDA publication date of the updated list and use that date as the reference point for applying the VAT exemption to covered medicines. The BIR’s language makes clear that the VAT exemption of the covered medicines and medical devices under the CREATE Act begins from the FDA publication date of the updates to the list.

This timing rule is especially relevant for businesses that process high volumes of medicine sales. A pharmacy chain, hospital billing office, or distributor may have transactions before and after the FDA publication date. Accounting teams should be careful not to apply a blanket VAT treatment across different periods without verifying when the updated exemption became effective for the specific medicines concerned.

Key Compliance Requirements for Businesses

RMC No. 72-2023 requires taxpayers to be guided by the FDA-endorsed updates and gives the circular wide publicity. In practical terms, affected businesses should first identify whether they sell or purchase medicines for cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness, or tuberculosis. These are the disease categories expressly mentioned in the circular for the inclusion of certain medicines.

Second, businesses should confirm whether any hypertension medicine in their product database is affected by the correction mentioned in the circular. A correction can create compliance risk when a product is mislabeled, miscoded, or treated under an outdated description in the accounting system. Tax teams should coordinate with pharmacists, procurement officers, and product managers to ensure that the medicine name, product code, and tax classification are consistent.

Third, businesses should check whether they carry the cancer medicine that was deleted from the VAT-exempt list. A deleted medicine should not continue to be tagged as VAT-exempt if it no longer qualifies under the updated list. Continuing to treat a deleted item as VAT-exempt may result in under-declaration of VATable sales or inaccurate sales documentation.

Fourth, taxpayers should preserve documentation showing the basis for their VAT treatment. For medicines treated as VAT-exempt, the supporting records should include the relevant FDA-published list or update, product identification, internal tax coding approvals, and the applicable effective date. This is particularly important for taxpayers that may later be asked to explain why VAT was not imposed on certain medicine sales.

Penalties and Risks for Non-Compliance

RMC No. 72-2023 does not impose a new penalty provision, surcharge, interest rate, or special fine. However, that does not mean the circular can be ignored. Incorrect VAT treatment may expose a taxpayer to the ordinary consequences of tax underpayment, inaccurate returns, improper invoicing, and assessment risk under existing tax rules.

For sellers, the risk is two-sided. If a VAT-exempt medicine is incorrectly treated as VATable, customers may be overcharged and the business may need to correct invoices, pricing, and customer accounts. If a deleted medicine is incorrectly treated as VAT-exempt, the seller may underreport VATable sales. In either case, the business may face reconciliation problems between inventory records, VAT returns, sales reports, and financial statements.

For buyers and institutional purchasers, the issue is also important. A hospital, clinic, or healthcare business purchasing medicines must ensure that purchase documentation properly reflects whether VAT was charged. Incorrect supplier invoices can affect cost recording, VAT reporting, and internal audit findings. A CFO or tax manager should not assume that suppliers have already updated their systems merely because the BIR has issued the circular.

Practical Steps for CFOs, Accountants, Pharmacies, and Healthcare Businesses

The immediate step is to obtain and review the updated FDA-published VAT-exempt medicines list referenced by RMC No. 72-2023. Businesses should compare the updated list against their inventory master file, product codes, tax mapping, and billing templates. The review should specifically cover medicines for cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness, and tuberculosis.

Businesses should then update their point-of-sale systems, enterprise resource planning systems, pharmacy management software, and invoice templates to reflect the proper VAT status. Any correction for a hypertension medicine should be reviewed carefully because a corrected entry may still be missed if the business relies only on older product descriptions. Any deleted cancer medicine should be flagged so that it is not inadvertently continued as a VAT-exempt product.

Accounting teams should also run a transaction review covering the period beginning on the FDA publication date of the updates. This helps identify whether sales were taxed or exempted correctly from the proper effective date. Where errors are discovered, management should consult tax counsel on whether invoice corrections, customer adjustments, return amendments, or voluntary compliance measures are appropriate.

Finally, businesses should document the internal decision-making process. A short tax memo, product mapping table, or compliance note can help show that the company acted in good faith and relied on the FDA-endorsed update published through RMC No. 72-2023. This is particularly helpful for pharmacy chains, hospitals, and distributors that may be reviewed by auditors or examined by the BIR.

How Ablola, Saribong & Gueco Can Help

RMC No. 72-2023 is a reminder that VAT compliance for medicines is not static. The tax treatment of pharmaceutical products may change when the FDA updates the official list, and businesses must be ready to adjust their systems, invoices, and VAT reporting immediately. For healthcare companies, pharmacies, hospitals, pharmaceutical distributors, and corporate accounting teams, the cost of delay is often found not in the circular itself but in the downstream errors in invoicing and tax reporting.

Ablola, Saribong & Gueco assists clients with BIR compliance, VAT classification reviews, tax risk assessments, invoicing controls, and responses to BIR audits involving healthcare, pharmaceutical, and regulated businesses. For legal advice on RMC No. 72-2023, VAT-exempt medicines, CREATE Act compliance, or BIR documentation requirements, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *